載入...
Recurrent Bilateral Strokes in a Patient Treated With Sipuleucel-T for Prostate Cancer
Sipuleucel-T is approved by the US Food and Drug Administration (FDA) for the treatment of castration-resistant prostate cancer (CRPC). Herein, we present a patient with recurrent bilateral embolic stroke who was on sipuleucel-T therapy for CRPC. Laboratory and imaging data didn’t reveal any source...
Na minha lista:
| 發表在: | Cureus |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Cureus
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8137308/ https://ncbi.nlm.nih.gov/pubmed/34036014 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.14596 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|